Darifenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder

被引：5

作者：

Khullar, V

机构：

来源：

JOURNAL OF UROLOGY | 2004年 / 171卷 / 04期

关键词：

D O I：

10.1016/S0022-5347(18)37753-X

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：131 / 131

页数：1

共 50 条

[1] Darifenacin:: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder
Chapple, CR
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1493 - 1500
[2] Darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA) for overactive bladder, does not prolong QT/QTc
Serra, DB
Affrime, MB
Bedigian, MP
Greig, G
Wang, Y
Danahay, H
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 633 - 633
[3] Darifenacin, a muscarinic receptor antagonist with selectivity for M3 receptors, reduces incontinence and nocturia in patients with overactive bladder
Hill, S
Khullar, V
NEUROUROLOGY AND URODYNAMICS, 2004, 23 (5-6) : 602 - 603
[4] Darifenacin, an M3 selective receptor antagonist (M3 SRA), is effective and well tolerated in elderly patients with Overactive Bladder.
Foote, JE
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : S126 - S127
[5] Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers
Kay, GG
Wesnes, KA
BJU INTERNATIONAL, 2005, 96 (07) : 1055 - 1062
[6] Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
Norman Zinner
John Tuttle
Leonard Marks
World Journal of Urology, 2005, 23 : 248 - 252
[7] Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
Zinner, N
Tuttle, J
Marks, L
WORLD JOURNAL OF UROLOGY, 2005, 23 (04) : 248 - 252
[8] Darifenacin:: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder
Zinner, Norman
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 511 - 523
[9] QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder
Serra, DB
Affrime, MB
Bedigian, MR
Greig, G
Milosavljev, S
Skerjanec, A
Wang, YB
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1038 - 1047
[10] Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder
Haab, F
Stewart, L
Dwyer, P
EUROPEAN UROLOGY, 2004, 45 (04) : 420 - 429

← 1 2 3 4 5 →